Tag: Oncobayes Progressing
-
OncoBayes progressing OB-001 to tackle ADC resistance and TKI brain penetration
LONDON, Oct. 7, 2026 /PRNewswire/ — OncoBayes, a privately held clinical-stage pharmaceutical company, today announced the successful completion of preclinical work with OB-001, demonstrating the product’s potential to tackle two major unmet needs in oncology: ADC resistance and the brain penetrati…
Latest News
About the Author
Your reliable go-to for precise and up-to-date information!
We are dedicated to accuracy, impartiality, and providing news as it unfolds, earning the trust of a wide audience. Keep up with real-time updates on the latest events and trends.